Premium
Antibody‐Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy
Author(s) -
Jerjian Taleen V.,
Glode Ashley E.,
Thompson Lisa A.,
O'Bryant Cindy L.
Publication year - 2016
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1687
Subject(s) - brentuximab vedotin , gemtuzumab ozogamicin , medicine , trastuzumab emtansine , trastuzumab , clinical trial , oncology , drug , cancer , monoclonal antibody , antibody drug conjugate , pharmacology , chemotherapy , breast cancer , lymphoma , antibody , immunology , cd33 , stem cell , hodgkin lymphoma , biology , cd34 , genetics
Antibody‐drug conjugates ( ADC s) combine highly specific monoclonal antibodies with potent cytotoxic drugs. Their synergy allows for targeted delivery of toxic drugs to cancer cells while sparing systemic exposure. In this review, we focus on the history and clinical applications of ADCs approved by the U.S. Food and Drug Administration ( FDA ) for the treatment of cancer and highlight new ADC s in the drug development pipeline. Three ADC s have received FDA approval thus far. Gemtuzumab ozogamicin, although withdrawn from the U.S. market, may still be an effective treatment modality in subsets of patients with acute myeloid leukemia. Brentuximab vedotin and ado‐trastuzumab emtansine have shown improved efficacy and safety data compared with standard chemotherapy for the treatment of advanced lymphoma and breast cancer, respectively. With a number of ADC s with promising preliminary data in the clinical trial pipeline, cancer therapy is moving forward from traditional chemotherapy to targeted treatment modalities driven by the specificity of monoclonal antibodies and advancing biotechnology.